medcitynews.com /4 days ago

Marrow Therapeutics Unveils $173M for ‘Trojan Horse’ Delivery of Blood Disorder Drugs

Sickle cell disease and beta thalassemia are the startup’s lead indications. While gene therapies are available for both blood disorders, Marrow executives say manufacturing and do...

Read source
biopharmadive.com /5 days ago

Marrow sets out to challenge genetic medicines for severe blood diseases

Armed with $173 million in venture funding, the startup is developing what it’s positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle...

Read source
pharmexec.com /6 days ago

<![CDATA[The Ron Lanton Report: Ossium Health's Bone Marrow Bank]]>

Read source
medcitynews.com /3 weeks ago

Patient Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics attributed one of the fatalities to a drug used to prepare patients for cell therapy and not to the cell therapy itself. But Artiva’s setbacks follow safety...

Read source
orthotw.com /1 month ago

PearlMatrix® P-15 Peptide Enhanced Bone Graft Receives Medicare New Technology Add-on Payment (NTAP), Helping Hospitals...

NTAP provides additional Medicare reimbursement to hospitals using PearlMatrix, the first and only bone growth accelerator demonstrating superior lumbar fusion speed.

Read source
cafepharma.com /1 month ago

MINERALYS THERAPEUTICS

MINERALYS THERAPEUTICS Anonymous (not verified) Mon, 09/28/2026 - 01:03 field_thread_url https://cafepharma.com/boards/threads/mineralys-therapeutics.71823...

Read source
medcitynews.com /1 month ago

Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer

The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera. Silence’s RNA therapy offers a different approach and...

Read source
healio.com /1 week ago

OSCA stem cell therapy imparts osteoarthritis structural changes

ORLANDO — A single-injection combination of osiramestrocel and an acellular cartilage matrix improved pain and triggered favorable structural changes in knee osteoarthritis, accord...

Read source
fightaging.org /1 month ago

Creation of Chimeric Antigen Receptor Natural Killer Cells in Situ via Messenger RNA Therapy

Messenger RNA (mRNA) can be delivered into tissues and cells by encapsulating it into lipid nanoparticles (LNPs), and then injecting the nanoparticles. A target cell engulfs a LNP,...

Read source
fightaging.org /1 month ago

Possible Approaches to Engineering Better Therapeutic Delivery of Mitochondria

Mitochondrial transplantation as a form of therapy to improve mitochondrial function in aged tissues has barely started as a going concern, and only a few patients have been treate...

Read source
orthotw.com /1 month ago

Small Lesion, Long Memory: Age and the Talar Marrow Stimulation Question

Does age change the bone marrow stimulation outcomes?

Read source
roi-nj.com /3 weeks ago

Made Scientific, CARR Biosystems create partnership to advance cell therapy manufacturing

Made Scientific Inc., a Princeton-based clinical and commercial cell therapy contract development and manufacturing organization (CDMO), and Clearwater, Fla.-based CARR Biosystems...

Read source
orthospinenews.com /1 month ago

PearlMatrix® P-15 Peptide Enhanced Bone Graft Receives Medicare New Technology Add-on Payment (NTAP), Helping Hospitals...

WESTMINSTER, Colo., Oct. 1, 2026 /PRNewswire/ — Cerapedics Inc., a commercial-stage musculoskeletal company dedicated to redefining the path to bone repair, today announced that…

Read source
prweb.com /4 days ago

MABT Appoints Professor Srinivasan Madhusudan to Its Scientific Advisory Board

MABT is a pharmaceutical company focused on the development and commercialization of novel therapeutic approaches and AI-enabled technologies. Our scientific and medical focus is o...

Read source
bioengineer.org /1 month ago

Liquid Radioembolic Aims Radiation Directly at Brain Tumors Via Their Own Blood Supply

Mount Sinai and Johnson & Johnson will collaboratively evaluate an investigational liquid radioembolic that combines Iodine-131 with TRUFILL n-BCA to embolize and irradiate bra...

Read source
medcitynews.com /1 week ago

Drug Approval Marks Another Win for Merck KGaA’s Rare Tumor Strategy

Merck KGaA drug Pimjetmi is now FDA approved for treating tenosynovial giant cell tumor. This drug complements other rare tumor assets the Germany-based drugmaker has acquired in a...

Read source
labiotech.eu /1 month ago

New Graft-versus-Host Disease treatments: What’s in the biotech pipeline in 2026?

Over the past decade, a succession of new GvHD treatments targeting different components of the immune response have been approved. The post New Graft-versus-Host Disease treatment...

Read source
timesofindia.indiatimes.com /1 month ago

Stanford blood cancer transplant therapy reaches first commercial patient

In a remarkable advancement, Stanford researchers have unveiled Orca-T therapy, which has recently received FDA approval. After two decades of rigorous development, this innovative...

Read source
bioengineer.org /3 weeks ago

Regenerating Bone Marrow Gives Transplanted Stem Cells a Lasting Boost in Mice

A mouse study found that hematopoietic stem cells engrafted during active bone marrow regeneration showed superior long-term reconstitution compared with cells engrafted after myel...

Read source
cafepharma.com /6 days ago

Vera Therapeutics

Vera Therapeutics Anonymous (not verified) Mon, 11/16/2026 - 00:40 field_thread_url https://cafepharma.com/boards/threads/vera-therapeutics.713115/...

Read source
cassling.com /3 weeks ago

Building a Scalable Theranostics Program: Five Lessons from Nebraska Cancer Specialists

Theranostics, also called radiotheranostics, combines targeted disease diagnosis and therapy into an integrated medical process for oncology providers. Although the field isn’t new...

Read source
pharmexec.com /1 month ago

<![CDATA[METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies]]&gt...

Read source
thehindubusinessline.com /1 month ago

Nucelion Therapeutics, VeGen Bio partner to manufacture CAR-T cell therapy in India

The collaboration will combine technology transfer, clinical and commercial manufacturing, and process optimisation to improve production economics and expand patient access

Read source
newswire.com /6 days ago

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Re...

Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig combination therapy ad...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.